作者
Nathan A Pennell, Gilbert H Daniels, Robert I Haddad, Douglas S Ross, Tracey Evans, Lori J Wirth, Panos H Fidias, Jennifer S Temel, Sarada Gurubhagavatula, Rebecca Suk Heist, John R Clark, Thomas J Lynch
发表日期
2008/3/1
期刊
Thyroid
卷号
18
期号
3
页码范围
317-323
出版商
Mary Ann Liebert, Inc.
简介
Objective: To determine the efficacy of gefitinib in patients with advanced thyroid cancer.
Design: In this open-label phase II trial, 27 patients with radioiodine-refractory, locally advanced, or metastatic thyroid cancer were treated with 250 mg of daily gefitinib. Histologic subtypes included papillary (41%), follicular (22%), anaplastic (19%), medullary (15%), and Hürthle cell carcinomas (4%). The primary endpoint was overall response rate. Secondary endpoints were toxicity, progression-free survival (PFS), and overall survival (OS).
Main outcomes: There were no objective responses among the 25 patients evaluated. After 3, 6, and 12 months of treatment, 48%, 24%, and 12% of patients had stable disease (SD), respectively. Median PFS and OS were 3.7 and 17.5 months, respectively. Five patients with SD had a decrease in thyroglobulin (Tg) to <90% of baseline that was maintained for at least 3 months.
Conclusions …
引用总数
学术搜索中的文章
NA Pennell, GH Daniels, RI Haddad, DS Ross, T Evans… - Thyroid, 2008